bioAffinity Technologies, Inc. (BIAF) Form 424B5 — Nov 3, 2026
bioAffinity Technologies filed a 424B5 prospectus supplement increasing its at-the-market offering capacity by up to $5,228,226 of common stock, sold through WallachBeth Capital under its May 2025 sales agreement. The company has already sold 114,672 shares for roughly $1.3 million under this program, and $4.0 million in the trailing twelve months under the Form S-3 I.B.6 limit. The supplement corrects a typographical error in the November 2, 2026 supplement, but the substantive change is the enlarged ATM capacity.
Key figures
- Gross Proceeds
- 5228226
- Offering Price
- 2.91
- Shares Offered
- Up to $5,228,226 of common stock (dollar-based ATM)
- Ib6 limit pct
- one-third of non-affiliate float
- Highest close 60d
- 15.27
- Shares already sold
- 114672
- Prior gross proceeds
- 1300000
- Non affiliate float value
- 27684678
- Prior 12m sales under ib6
- 4000000
- Shares outstanding non affiliates
- 1813011
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.